All In Biotech

Drug Trial Radar · NCT07371663

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

An Open-Label, Multicenter Phase Ib/II Clinical Trial of TCC1727 in Combination With Benmelstobart/Olaparib/Topotecan for Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

266

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Sep 30, 2028

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Jan 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with advanced solid tumors. The Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart /olaparib/topotecanin selected advanced solid tumor indications. The study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination 2 and Combination 3will be based on clinical data from Combination 1.

Conditions

  • Solid Cancers
  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • Gastric (Stomach) Cancer
  • Endometrial Cancer
  • Malignant Melanoma

Interventions

  • TCC1727 tablet 90mgDrug

    TCC1727 tablets 90 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression

  • TCC1727 tablet 120mgDrug

    TCC1727 tablets 120 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression

  • TCC1727 tablet 160mgDrug

    TCC1727 tablets 160 mg, orally, twice daily (bid), continuous dosing in 21-day cycles until disease progression

  • benmelstobart InjectionCombination product

    Administer 1200 mg per dose via intravenous infusion on Day 1 of every 3-week cycle until disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib:To determine dose-limiting toxicity (DLT) at each dose levelTime frame: 21 Days
  2. MTDTime frame: 21 days
  3. RP2DTime frame: 21 days
  4. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: 21days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.